Xtant Medical Holdings, Inc.
AMEX:XTNTMedical - Devices
-$0.00 today
- Market cap
- $50.37M
- Beta
- -0.17
- P/E (TTM)
- 33.4
- EPS (TTM)
- $0.01
Volume 0.16M
Average 0.16M
XTNT Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Xtant Medical Holdings, Inc.AMEX: XTNT
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $1.64M, compared with -$890K a year earlier. Trailing-twelve-month accounts payables was -$586K.
Context
- Accounts payables amounted to 2.3% of revenue in FY2025, up 1.4 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near $1.64M or moves back toward the trailing-twelve-month quarterly average of -$146.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (3.12M) USD
- Year-over-year change
- -401.7%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.12M) | -401.7% |
| FY2024 | 2024-12-31 | 1.03M | -65.3% |
| FY2023 | 2023-12-31 | 2.98M | +240.6% |
| FY2022 | 2022-12-31 | 875K | +363.6% |
| FY2021 | 2021-12-31 | (332K) | — |
Accounts Payables vs competitors
How XTNT compares with its peers on the latest reported figures
- XTNT's LTM Mar 2026 accounts payables of $586K is the 4th largest of the 8 companies compared; the peer median is $250K.
- Its year-over-year change of +67.9% is the 3rd highest of 8, against a peer median of +34.1%.
- Accounts payables amounts to 0.5% of revenue for XTNT, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.03M | +38.0% | +2.5% | 5.9% | |
| LTM Mar 2026 | $1.37M | -139.9% | +113.5% | 1.9% | |
| LTM Mar 2026 | $1.06M | +335.4% | +20.7% | 1.0% | |
| LTM Mar 2026 | $586K | +67.9% | — | 0.5% | |
| LTM Mar 2026 | $275K | +34.1% | +74.3% | 0.5% | |
| LTM Mar 2026 | $250K | +278.6% | -15.3% | 4.9% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $162.28K | -48.5% | +37.9% | — |
| LTM Mar 2026 | $36K | -90.9% | -51.5% | — | |
| Peer median (excluding XTNT) | $250K | +34.1% | +20.7% | 1.9% | |
Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.85M) | (8.49M) | 660K | (16.45M) | 4.97M |
| Depreciation & Amortization | 1.33M | 1.29M | 3.17M | 4.22M | 5.22M |
| Deferred Income Tax | 0 | 0 | (1.9M) | 21K | 0 |
| Stock-Based Compensation | 2.21M | 2.46M | 2.74M | 4.12M | 2.89M |
| Change in Working Capital | 793K | (2.81M) | (3.63M) | (5.35M) | (3.05M) |
| Accounts Receivables | (319K) | (3.94M) | (8.74M) | (755K) | (591K) |
| Inventory | 2.62M | (1.15M) | (1.89M) | (2.49M) | (2M) |
| Accounts Payables | (332K) | 875K | 2.98M | 1.03M | (3.12M) |
| Other Working Capital | (1.18M) | 1.41M | 4.01M | (3.13M) | 2.66M |
| Other Non-Cash Items | 954K | 2.2M | (10.55M) | 1.54M | 2.5M |
| Operating Cash Flow | 439K | (5.34M) | (9.52M) | (11.9M) | 12.55M |
| Capital Expenditures | (2.12M) | (1.76M) | (1.46M) | (4.11M) | (2.38M) |
| Acquisitions (Net) | 0 | 0 | (23.5M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 225K | 205K | 175K | 383K | 10.28M |
| Investing Cash Flow | (1.89M) | (1.56M) | (24.78M) | (3.73M) | 7.9M |
| Debt Repayment | (592K) | (291K) | 6.18M | 12.43M | (9.33M) |
| Common Stock Issued | 18.43M | 9.31M | 14.01M | 4.46M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (65K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (337K) | 9.07M | (500K) | (816K) | (175K) |
| Financing Cash Flow | 17.5M | 9.02M | 19.69M | 16.07M | (9.57M) |
| Effect of Forex Changes | 0 | 0 | 24K | (149K) | 232K |
| Net Change in Cash | 16.05M | 2.12M | (14.58M) | 298K | 11.11M |
| Free Cash Flow | (1.68M) | (7.11M) | (10.97M) | (16.01M) | 10.16M |
Xtant Medical Holdings, Inc.
AMEX:XTNT
Intrinsic Alpha fair value
Locked
Current Price
$0.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.